ERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginning
Open Access
- 6 August 2021
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
- Vol. 6, 132-135
- https://doi.org/10.25259/ijmio_10_2021
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab EmtansineJCO Precision Oncology, 2019
- Cholangiocarcinoma: Epidemiology and risk factorsLiver International, 2019
- Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published dataCritical Reviews in Oncology/Hematology, 2019
- Gallbladder cancer – no improvement in survival over time in a Swedish populationActa Oncologica, 2018
- The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancerTherapeutic Advances in Gastroenterology, 2017
- Genomic spectra of biliary tract cancerNature Genetics, 2015
- Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.Journal of Clinical Oncology, 2015
- Indian Council of Medical Research consensus document for the management of gall bladder cancerIndian Journal of Medical and Paediatric Oncology, 2015
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trialsAnnals of Oncology, 2013
- Population-based study to estimate prevalence and determine risk factors of gallbladder diseases in the rural Gangetic basin of North IndiaHPB, 2011